Avigen deal

Avigen received exclusive worldwide rights to a multidrug resistance gene from PARTEQ, the technology transfer arm of Queen's University at Kingston, Ontario. The gene expresses a multidrug resistance-associated protein that causes cells to become tolerant to otherwise toxic levels of cytotoxic drugs.

Avigen will use its adeno-associated virus vectors to transfer the gene into normal bone marrow cells of patients undergoing chemotherapy. The modified cells then will be reinjected into the patient. ...